MedTrace Logo

SGLT2 Inhibitor for Severe Tricuspid Regurgitation

NCT05686616 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-01-17

No results posted yet for this study

Summary

The purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (TR) in patients with isolated severe TR.

Conditions

  • Tricuspid Regurgitation

Interventions

DRUG

Dapagliflozin Propanediol Hydrate 12.3 mg

Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Sung Ji Park, MD, PhD · Heart Vascular Stroke Institute, Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-13
Primary Completion
2024-04-13
Completion
2025-03-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686616 on ClinicalTrials.gov